Tower Research Capital (TRC)’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $283K | Buy |
1,418
+661
| +87% | +$131K | 0.01% | 1345 |
|
|
2025
Q4 | $143K | Buy |
757
+335
| +79% | +$64.4K | ﹤0.01% | 1704 |
|
|
2025
Q3 | $74.8K | Sell |
422
-1,247
| -75% | -$185K | ﹤0.01% | 2232 |
|
|
2025
Q2 | $190K | Buy |
1,669
+1,574
| +1,657% | +$168K | 0.01% | 1827 |
|
|
2025
Q1 | $9.99K | Sell |
95
-715
| -88% | -$80.9K | ﹤0.01% | 3694 |
|
|
2024
Q4 | $86.8K | Buy |
810
+616
| +318% | +$69.6K | ﹤0.01% | 2224 |
|
|
2024
Q3 | $19.4K | Sell |
194
-1,817
| -90% | -$183K | ﹤0.01% | 3252 |
|
|
2024
Q2 | $169K | Buy |
2,011
+307
| +18% | +$24.4K | ﹤0.01% | 2200 |
|
|
2024
Q1 | $125K | Sell |
1,704
-2,144
| -56% | -$158K | ﹤0.01% | 1710 |
|
|
2023
Q4 | $275K | Buy |
3,848
+2,745
| +249% | +$162K | ﹤0.01% | 1839 |
|
|
2023
Q3 | $66.1K | Buy |
1,103
+779
| +240% | +$51.3K | ﹤0.01% | 2318 |
|
|
2023
Q2 | $23.4K | Sell |
324
-195
| -38% | -$14.6K | ﹤0.01% | 3247 |
|
|
2023
Q1 | $38K | Sell |
519
-642
| -55% | -$45.6K | ﹤0.01% | 2753 |
|
|
2022
Q4 | $78K | Sell |
1,161
-4,437
| -79% | -$288K | ﹤0.01% | 2023 |
|
|
2022
Q3 | $301K | Sell |
5,598
-3,380
| -38% | -$199K | ﹤0.01% | 1549 |
|
|
2022
Q2 | $500K | Buy |
8,978
+6,099
| +212% | +$346K | 0.01% | 1137 |
|
|
2022
Q1 | $202K | Sell |
2,879
-2,871
| -50% | -$208K | ﹤0.01% | 1720 |
|
|
2021
Q4 | $554K | Buy |
5,750
+3,475
| +153% | +$321K | 0.01% | 1053 |
|
|
2021
Q3 | $198K | Buy |
2,275
+638
| +39% | +$49.3K | 0.01% | 1832 |
|
|
2021
Q2 | $134K | Sell |
1,637
-160
| -9% | -$13.3K | ﹤0.01% | 2191 |
|
|
2021
Q1 | $171K | Buy |
1,797
+406
| +29% | +$38.4K | ﹤0.01% | 2145 |
|
|
2020
Q4 | $86K | Sell |
1,391
-685
| -33% | -$39.1K | ﹤0.01% | 2499 |
|
|
2020
Q3 | $123K | Sell |
2,076
-3,520
| -63% | -$240K | ﹤0.01% | 2983 |
|
|
2020
Q2 | $390K | Buy |
5,596
+5,548
| +11,558% | +$352K | 0.02% | 1229 |
|
|
2020
Q1 | $2K | Sell |
48
-3,522
| -99% | -$200K | ﹤0.01% | 2601 |
|
|
2019
Q4 | $232K | Buy |
3,570
+3,155
| +760% | +$211K | 0.02% | 530 |
|
|
2019
Q3 | $26K | Buy |
415
+50
| +14% | +$3.14K | ﹤0.01% | 2295 |
|
|
2019
Q2 | $26K | Buy |
365
+238
| +187% | +$17.5K | ﹤0.01% | 2008 |
|
|
2019
Q1 | $10K | Sell |
127
-192
| -60% | -$14.5K | ﹤0.01% | 2679 |
|
|
2018
Q4 | $27K | Buy |
+319
| New | +$34K | ﹤0.01% | 1706 |
|
|
2018
Q3 | – | Sell |
-24
| Closed | -$3K | – | 4034 |
|
|
2018
Q2 | $3K | Buy |
+24
| New | +$2.68K | ﹤0.01% | 3235 |
|
|
2018
Q1 | – | Sell |
-231
| Closed | -$20K | – | 3579 |
|
|
2017
Q4 | $20K | Sell |
231
-2,085
| -90% | -$181K | ﹤0.01% | 2068 |
|
|
2017
Q3 | $197K | Buy |
2,316
+1,939
| +514% | +$154K | 0.02% | 781 |
|
|
2017
Q2 | $29K | Buy |
+377
| New | +$26.4K | ﹤0.01% | 1022 |
|
|
2017
Q1 | – | Sell |
-313
| Closed | -$20K | – | 3531 |
|
|
2016
Q4 | $20K | Buy |
313
+133
| +74% | +$8.39K | ﹤0.01% | 2141 |
|
|
2016
Q3 | $11K | Sell |
180
-14
| -7% | -$1.03K | ﹤0.01% | 2002 |
|
|
2016
Q2 | $14K | Buy |
+194
| New | +$14.4K | ﹤0.01% | 2532 |
|
|
2016
Q1 | – | Sell |
-268
| Closed | -$18K | – | 4571 |
|
|
2015
Q4 | $18K | Buy |
+268
| New | +$16.5K | ﹤0.01% | 1409 |
|
|
2015
Q3 | – | Sell |
-510
| Closed | -$32K | – | 4430 |
|
|
2015
Q2 | $32K | Sell |
510
-2,090
| -80% | -$114K | ﹤0.01% | 1717 |
|
|
2015
Q1 | $125K | Buy |
2,600
+2,119
| +441% | +$81.2K | 0.02% | 721 |
|
|
2014
Q4 | $16K | Buy |
481
+42
| +10% | +$1.37K | ﹤0.01% | 1751 |
|
|
2014
Q3 | $13K | Sell |
439
-874
| -67% | -$29K | ﹤0.01% | 2640 |
|
|
2014
Q2 | $51K | Buy |
1,313
+954
| +266% | +$38.7K | 0.01% | 1281 |
|
|
2014
Q1 | $15K | Buy |
+359
| New | +$15K | ﹤0.01% | 2177 |
|
|
2013
Q4 | – | Sell |
-43
| Closed | -$1K | – | 4720 |
|
|
2013
Q3 | $1K | Sell |
43
-3,647
| -99% | -$103K | ﹤0.01% | 4313 |
|
|
2013
Q2 | $86K | Buy |
+3,690
| New | +$66.4K | 0.01% | 587 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
Tower Research Capital (TRC)'s LGND Position: Q1 2026 in Review
Tower Research Capital (TRC) increased its Ligand Pharmaceuticals (LGND) stake by 87% in Q1 2026, buying an estimated $131K and bringing the position to 1,418 shares worth $283K. The position accounts for 0.01% of the portfolio, ranked #1345.
Tower Research Capital (TRC) first reported a position in LGND in Q2 2013 and has held it in 46 quarters since. The position peaked at $554K in Q4 2021. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Tower Research Capital (TRC) held 1,418 shares of Ligand Pharmaceuticals worth $283K as of Q1 2026.
- Tower Research Capital (TRC) bought 661 Ligand Pharmaceuticals shares in Q1 2026, an estimated $131K.
- Ligand Pharmaceuticals made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #1345 holding.
- Tower Research Capital (TRC) first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 46 quarters since.
- Tower Research Capital (TRC)'s Ligand Pharmaceuticals position peaked at $554K in Q4 2021.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.